Table of Contents 3
List of Tables 5
List of Figures 5
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Oxford Immunotec Enters into Licensing Agreement with IDIBELL 11
Minoryx Therapeutics Enters Into Licensing Agreement with Universitat de Barcelona and Institut de Investigacio Biomedica de Bellvitge 12
Minoryx Therapeutics Enters into Licensing Agreement with Bellvittge Biomedical 13
Histocell Enters Into Licensing Agreement With IDIBELL For Acute Pulmonary Diseases Patent 14
Bellvitge Biomedical Research Institute - Key Competitors 15
Bellvitge Biomedical Research Institute - Key Employees 16
Bellvitge Biomedical Research Institute - Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Legal and Regulatory 18
Mar 23, 2018: IDIBELL obtains the TECNIO certification as a public technology facilitator 18
Government and Public Interest 19
Sep 25, 2018: IDIBELL researchers receive AECC grants on World Cancer Research Day 19
Aug 11, 2018: A new epigenetic signature predicts the response to immunotherapy in lung cancer 21
Aug 01, 2018: The biochemical signature of the synapse in a model of Down syndrome is identified with high resolution 22
Jun 27, 2018: New combined treatment shows promise in Hepatocellular Carcinoma 23
Jun 11, 2018: New epigenetic drug against Mantle Cell Lymphoma 24
May 14, 2018: Scientists discover a variation of the genome predisposing to Alzheimer's disease 25
Apr 20, 2018: The EPICUP Project receives a Pfizer Foundation Innovation award 26
Apr 05, 2018: A potential new therapeutic target for Ewing sarcoma 27
Mar 15, 2018: Creation of a web platform for the identification of fronto-subcortical connectivity alterations in brain disorders 28
Feb 20, 2018: RAC1 protein could be a new therapeutic target to fight neurodegeneration in Parkinson's disease 29
Jan 31, 2018: EU empowers four IDIBELL researchers with Marie Sklodowska-Curie Individual Fellowships 31
Jan 04, 2018: IDIBELL-ICO researchers identify a new therapeutic target to fight metastasis in ovarian cancer 32
Jan 04, 2018: IDIBELL researchers - ICO identify a new therapeutic target to combat metastasis in ovarian cancer 33
Jan 02, 2018: Alex Vaquero is awarded 200,000 euros from Worldwide Cancer Research to better understand the origin of cancer 34
Dec 19, 2017: Mild obsessive-compulsive symptoms are associated with variations of cerebral anatomy in healthy children 35
Dec 18, 2017: European project EU-TRAIN to improve the results in kidney transplant receives more than six million euros 36
Nov 21, 2017: The isoforms of the HP1 protein differentially regulate the organization and structure of heterochromatin 37
Oct 09, 2017: A new genetic marker accounts for up to 1.4% of cases of hereditary colon cancer 38
Oct 03, 2017: IDIBELL scientists identify a key regulator of the acquisition of immune tolerance to tumor cells in cancer patients 39
Jan 31, 2017: European experts highlight the potential of xenografts in personalized oncology 40
Product News 41
Jun 07, 2018: First photoactive drug to fight Parkinson's disease 41
May 09, 2018: A new drug shows preclinical efficacy in Rett syndrome 43
Apr 11, 2017: First photoactive drug for pain treatments 44
Jan 11, 2018: ICO-IDIBELL researchers successfully test a new combination therapy in sarcomas 46
Jan 11, 2018: IDIBELL researchers successfully test a new combination therapy in sarcomas 47
Other Significant Developments 48
Jun 22, 2018: CRISPR-editing of a single aminoacid make a whole animal more resistant to cisplatin-based chemotherapy 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Key Facts 2
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bellvitge Biomedical Research Institute, Deals By Therapy Area, 2012 to YTD 2018 9
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oxford Immunotec Enters into Licensing Agreement with IDIBELL 11
Minoryx Therapeutics Enters Into Licensing Agreement with Universitat de Barcelona and Institut de Investigacio Biomedica de Bellvitge 12
Minoryx Therapeutics Enters into Licensing Agreement with Bellvittge Biomedical 13
Histocell Enters Into Licensing Agreement With IDIBELL For Acute Pulmonary Diseases Patent 14
Bellvitge Biomedical Research Institute, Key Competitors 15
Bellvitge Biomedical Research Institute, Key Employees 16

List of Figures
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9